MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA
February 02, 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
January 13, 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive...
MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT
October 14, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced...
MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL
October 12, 2020 08:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced...
MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER INTERVENTIONAL STUDY OF ARTISHIELD™ AGAINST COVID-19
October 07, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
TOP-LINE DATA ANTICIPATED IN FOURTH QUARTER 2020 AGOURA HILLS, California, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β...
MATEON THERAPEUTICS TO INITIATE COMMERCIALIZATION OF ARTISHIELD™.
October 05, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that...
MATEON’S GLOBAL STUDY FOR ARTEMISININ INTERVENTION AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN INDIA.
September 14, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its...
MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL STUDY TO TEST ARTEMISININ AS A TREATMENT FOR COVID-19 IN INDIA
August 04, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, will be working together with Abiogenesis to initiate ARTI-19...
MATEON AND ASILI RESEARCH ALLIANCE ENTER INTO PARTNERSHIP FOR THE DEVELOPMENT OF ARTEMISININ AGAINST COVID-19
July 20, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today the launch of its global observational study...
Mateon Therapeutics to fund observational studies of Artemisinin in developing countries.
July 13, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
Agoura Hills, California, July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for...